In this context, FCRL gene expression should be evaluated in future studies on patients with other forms of thyrotoxicosis, such as, e.g., toxic nodular goiter or iatrogenic thyrotoxicosis. This evidence concerns the gene FCRLA and thyrotoxicosis.